239 related articles for article (PubMed ID: 27166673)
1. Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study.
Schuster C; Akslen LA; Straume O
PLoS One; 2016; 11(5):e0155242. PubMed ID: 27166673
[TBL] [Abstract][Full Text] [Related]
2. Predictive value of angiogenic proteins in patients with metastatic melanoma treated with bevacizumab monotherapy.
Schuster C; Akslen LA; Stokowy T; Straume O
J Pathol Clin Res; 2019 Jan; 5(1):53-62. PubMed ID: 30225999
[TBL] [Abstract][Full Text] [Related]
3. The correlation of angiogenesis with metastasis in primary cutaneous melanoma: a comparative analysis of microvessel density, expression of vascular endothelial growth factor and basic fibroblastic growth factor.
Demirkesen C; Büyükpinarbaşili N; Ramazanoğlu R; Oğuz O; Mandel NM; Kaner G
Pathology; 2006 Apr; 38(2):132-7. PubMed ID: 16581653
[TBL] [Abstract][Full Text] [Related]
4. Suppression of melanoma-associated neoangiogenesis by bevacizumab.
Jaissle GB; Ulmer A; Henke-Fahle S; Fierlbeck G; Bartz-Schmidt KU; Szurman P
Arch Dermatol; 2008 Apr; 144(4):525-7. PubMed ID: 18427047
[TBL] [Abstract][Full Text] [Related]
5. Microvessel density and endothelial cell proliferation levels in colorectal liver metastases from patients given neo-adjuvant cytotoxic chemotherapy and bevacizumab.
Eefsen RL; Engelholm L; Willemoe GL; Van den Eynden GG; Laerum OD; Christensen IJ; Rolff HC; Høyer-Hansen G; Osterlind K; Vainer B; Illemann M
Int J Cancer; 2016 Apr; 138(7):1777-84. PubMed ID: 26510166
[TBL] [Abstract][Full Text] [Related]
6. Bevacizumab treatment of meningeal melanoma metastases.
Simonsen TG; Gaustad JV; Rofstad EK
J Transl Med; 2020 Jan; 18(1):13. PubMed ID: 31915016
[TBL] [Abstract][Full Text] [Related]
7. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer.
Straume O; Shimamura T; Lampa MJ; Carretero J; Øyan AM; Jia D; Borgman CL; Soucheray M; Downing SR; Short SM; Kang SY; Wang S; Chen L; Collett K; Bachmann I; Wong KK; Shapiro GI; Kalland KH; Folkman J; Watnick RS; Akslen LA; Naumov GN
Proc Natl Acad Sci U S A; 2012 May; 109(22):8699-704. PubMed ID: 22589302
[TBL] [Abstract][Full Text] [Related]
8. Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression.
Straume O; Akslen LA
Am J Pathol; 2002 Mar; 160(3):1009-19. PubMed ID: 11891198
[TBL] [Abstract][Full Text] [Related]
9. S100A13 is a new angiogenic marker in human melanoma.
Massi D; Landriscina M; Piscazzi A; Cosci E; Kirov A; Paglierani M; Di Serio C; Mourmouras V; Fumagalli S; Biagioli M; Prudovsky I; Miracco C; Santucci M; Marchionni N; Tarantini F
Mod Pathol; 2010 Jun; 23(6):804-13. PubMed ID: 20208480
[TBL] [Abstract][Full Text] [Related]
10. Stromal expression of heat-shock protein 27 is associated with worse clinical outcome in patients with colorectal cancer lung metastases.
Schweiger T; Nikolowsky C; Starlinger P; Traxler D; Zimmermann M; Birner P; Hegedüs B; Dome B; Bergmann M; Mildner M; Klepetko W; Hoetzenecker K; Ankersmit HJ
PLoS One; 2015; 10(3):e0120724. PubMed ID: 25793600
[TBL] [Abstract][Full Text] [Related]
11. Blood-based biomarkers for monitoring antiangiogenic therapy in non-small cell lung cancer.
Rodríguez Garzotto A; Díaz-García CV; Agudo-López A; Prieto García E; Ponce S; López-Martín JA; Paz-Ares L; Iglesias L; Agulló-Ortuño MT
Med Oncol; 2016 Oct; 33(10):105. PubMed ID: 27568331
[TBL] [Abstract][Full Text] [Related]
12. Targeting Syndecan-1, a molecule implicated in the process of vasculogenic mimicry, enhances the therapeutic efficacy of the L19-IL2 immunocytokine in human melanoma xenografts.
Orecchia P; Conte R; Balza E; Pietra G; Mingari MC; Carnemolla B
Oncotarget; 2015 Nov; 6(35):37426-42. PubMed ID: 26460958
[TBL] [Abstract][Full Text] [Related]
13. VEGF
Boudria A; Abou Faycal C; Jia T; Gout S; Keramidas M; Didier C; Lemaître N; Manet S; Coll JL; Toffart AC; Moro-Sibilot D; Albiges-Rizo C; Josserand V; Faurobert E; Brambilla C; Brambilla E; Gazzeri S; Eymin B
Oncogene; 2019 Feb; 38(7):1050-1066. PubMed ID: 30194450
[TBL] [Abstract][Full Text] [Related]
14. Expression, prognostic and predictive impact of VEGF and bFGF in non-small cell lung cancer.
Farhat FS; Tfayli A; Fakhruddin N; Mahfouz R; Otrock ZK; Alameddine RS; Awada AH; Shamseddine A
Crit Rev Oncol Hematol; 2012 Nov; 84(2):149-60. PubMed ID: 22494932
[TBL] [Abstract][Full Text] [Related]
15. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival.
Paiva TF; de Jesus VH; Marques RA; da Costa AA; de Macedo MP; Peresi PM; Damascena A; Rossi BM; Begnami MD; de Lima VC
BMC Cancer; 2015 Sep; 15():643. PubMed ID: 26394830
[TBL] [Abstract][Full Text] [Related]
16. Expression of angiogenic growth factors VEGF, bFGF and ANG1 in colon cancer after bevacizumab treatment in vitro: A potential self-regulating mechanism.
Zhao M; Yu Z; Li Z; Tang J; Lai X; Liu L
Oncol Rep; 2017 Jan; 37(1):601-607. PubMed ID: 27840995
[TBL] [Abstract][Full Text] [Related]
17. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer.
Xu L; Duda DG; di Tomaso E; Ancukiewicz M; Chung DC; Lauwers GY; Samuel R; Shellito P; Czito BG; Lin PC; Poleski M; Bentley R; Clark JW; Willett CG; Jain RK
Cancer Res; 2009 Oct; 69(20):7905-10. PubMed ID: 19826039
[TBL] [Abstract][Full Text] [Related]
18. Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer.
Gampenrieder SP; Hufnagl C; Brechelmacher S; Huemer F; Hackl H; Rinnerthaler G; Romeder F; Monzo Fuentes C; Morre P; Hauser-Kronberger C; Mlineritsch B; Greil R
Pharmacogenomics J; 2017 Jul; 17(4):344-350. PubMed ID: 27139155
[TBL] [Abstract][Full Text] [Related]
19. Dacarbazine in combination with bevacizumab for the treatment of unresectable/metastatic melanoma: a phase II study.
Ferrucci PF; Minchella I; Mosconi M; Gandini S; Verrecchia F; Cocorocchio E; Passoni C; Pari C; Testori A; Coco P; Munzone E
Melanoma Res; 2015 Jun; 25(3):239-45. PubMed ID: 25746039
[TBL] [Abstract][Full Text] [Related]
20. Angiogenesis and vascular growth factor receptor expression in malignant melanoma.
Lin EY; Piepkorn M; Garcia R; Byrd D; Tsou R; Isik FF
Plast Reconstr Surg; 1999 Nov; 104(6):1666-74. PubMed ID: 10541167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
